Brokerages expect Boston Scientific Corporation (NYSE:BSX) to report sales of $2.35 billion for the current quarter, Zacks Investment Research reports. Ten analysts have issued estimates for Boston Scientific Corporation’s earnings, with estimates ranging from $2.32 billion to $2.37 billion. Boston Scientific Corporation posted sales of $2.19 billion in the same quarter last year, which suggests a positive year-over-year growth rate of 7.3%. The firm is scheduled to issue its next quarterly earnings report on Thursday, February 1st.

On average, analysts expect that Boston Scientific Corporation will report full-year sales of $2.35 billion for the current year, with estimates ranging from $8.96 billion to $9.01 billion. For the next financial year, analysts forecast that the company will report sales of $9.65 billion per share, with estimates ranging from $9.54 billion to $9.77 billion. Zacks’ sales calculations are an average based on a survey of research analysts that that provide coverage for Boston Scientific Corporation.

Boston Scientific Corporation (NYSE:BSX) last posted its quarterly earnings data on Thursday, October 26th. The medical equipment provider reported $0.31 earnings per share for the quarter, hitting the consensus estimate of $0.31. Boston Scientific Corporation had a return on equity of 23.60% and a net margin of 9.55%. The business had revenue of $2.22 billion during the quarter, compared to analysts’ expectations of $2.21 billion. During the same quarter in the previous year, the firm earned $0.27 EPS. The firm’s revenue was up 5.6% compared to the same quarter last year.

Several brokerages recently issued reports on BSX. Zacks Investment Research upgraded Boston Scientific Corporation from a “sell” rating to a “hold” rating in a research note on Monday, July 31st. UBS AG restated a “buy” rating and set a $31.00 price target (up from $30.00) on shares of Boston Scientific Corporation in a research note on Tuesday, August 1st. Oppenheimer Holdings, Inc. reiterated a “hold” rating on shares of Boston Scientific Corporation in a research note on Wednesday, August 9th. Cowen and Company reiterated a “buy” rating and issued a $32.00 price objective (up from $31.00) on shares of Boston Scientific Corporation in a research note on Friday, July 28th. Finally, BidaskClub lowered Boston Scientific Corporation from a “buy” rating to a “hold” rating in a research note on Tuesday, July 25th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $30.77.

COPYRIGHT VIOLATION WARNING: “Analysts Anticipate Boston Scientific Corporation (BSX) Will Post Quarterly Sales of $2.35 Billion” was posted by Watch List News and is the property of of Watch List News. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be read at https://www.watchlistnews.com/analysts-anticipate-boston-scientific-corporation-bsx-will-post-quarterly-sales-of-2-35-billion/1711579.html.

In related news, EVP Michael P. Phalen sold 15,500 shares of the firm’s stock in a transaction on Tuesday, August 29th. The stock was sold at an average price of $26.87, for a total transaction of $416,485.00. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Timothy A. Pratt sold 10,000 shares of the firm’s stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $28.22, for a total value of $282,200.00. Following the sale, the executive vice president now directly owns 164,681 shares in the company, valued at approximately $4,647,297.82. The disclosure for this sale can be found here. Insiders have sold a total of 508,864 shares of company stock worth $14,581,669 in the last ninety days. 0.74% of the stock is currently owned by company insiders.

A number of hedge funds have recently added to or reduced their stakes in the business. Capital World Investors increased its holdings in Boston Scientific Corporation by 1.6% during the 2nd quarter. Capital World Investors now owns 101,914,290 shares of the medical equipment provider’s stock worth $2,825,064,000 after purchasing an additional 1,611,442 shares in the last quarter. BlackRock Inc. increased its holdings in Boston Scientific Corporation by 4.6% during the 2nd quarter. BlackRock Inc. now owns 100,184,511 shares of the medical equipment provider’s stock worth $2,777,113,000 after purchasing an additional 4,439,966 shares in the last quarter. Vanguard Group Inc. increased its holdings in Boston Scientific Corporation by 2.8% during the 2nd quarter. Vanguard Group Inc. now owns 93,657,300 shares of the medical equipment provider’s stock worth $2,596,181,000 after purchasing an additional 2,522,556 shares in the last quarter. Janus Henderson Group PLC increased its holdings in Boston Scientific Corporation by 22,491.6% during the 2nd quarter. Janus Henderson Group PLC now owns 38,862,599 shares of the medical equipment provider’s stock worth $1,077,270,000 after purchasing an additional 38,690,577 shares in the last quarter. Finally, Winslow Capital Management LLC increased its holdings in Boston Scientific Corporation by 21.9% during the 2nd quarter. Winslow Capital Management LLC now owns 11,212,783 shares of the medical equipment provider’s stock worth $310,818,000 after purchasing an additional 2,011,640 shares in the last quarter. Hedge funds and other institutional investors own 90.50% of the company’s stock.

Boston Scientific Corporation (NYSE:BSX) opened at $28.26 on Friday. Boston Scientific Corporation has a 12 month low of $19.67 and a 12 month high of $29.93. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.50 and a current ratio of 0.72. The stock has a market capitalization of $38,830.00, a PE ratio of 23.21, a P/E/G ratio of 2.19 and a beta of 0.99.

Boston Scientific Corporation Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Get a free copy of the Zacks research report on Boston Scientific Corporation (BSX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Boston Scientific Corporation (NYSE:BSX)

Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.